Clinical potential of brodalumab in the management of psoriasis: the evidence to date

Laura F Sandoval,1 Brooke Williams,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Scie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sandoval LF, Williams B, Feldman SR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/e460669aee4546c284912a052ce96d84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e460669aee4546c284912a052ce96d84
record_format	dspace
spelling	oai:doaj.org-article:e460669aee4546c284912a052ce96d842021-12-02T07:36:54ZClinical potential of brodalumab in the management of psoriasis: the evidence to date2230-326Xhttps://doaj.org/article/e460669aee4546c284912a052ce96d842015-03-01T00:00:00Zhttp://www.dovepress.com/clinical-potential-of-brodalumab-in-the-management-of-psoriasis-the-ev-peer-reviewed-article-PTThttps://doaj.org/toc/2230-326X Laura F Sandoval,1 Brooke Williams,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Abstract: Brodalumab is an anti-IL-17 receptor monoclonal antibody currently in development for the treatment of moderate-to-severe plaque psoriasis. With many systemic psoriasis therapies to choose from, and several newer agents in development, physicians need up to date evidence for the use of these drugs. A PubMed search was conducted through August 1, 2014 to identify randomized controlled trials and systematic reviews of brodalumab for the treatment of psoriasis. Results of Phase I and II trials, as well as a few smaller studies, have provided promising data on efficacy, safety, health-related quality of life, pharmacokinetics, and changes in lesional skin. Early Phase III data continue to support the use of brodalumab as a potentially valuable option for the treatment of psoriasis. Keywords: anti-interleukin-17, psoriasis, biologic agents, efficacy, safety, systemic therapySandoval LFWilliams BFeldman SRDove Medical PressarticleDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2015, Iss default, Pp 35-41 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803
spellingShingle	Dermatology RL1-803 Sandoval LF Williams B Feldman SR Clinical potential of brodalumab in the management of psoriasis: the evidence to date
description	Laura F Sandoval,1 Brooke Williams,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Abstract: Brodalumab is an anti-IL-17 receptor monoclonal antibody currently in development for the treatment of moderate-to-severe plaque psoriasis. With many systemic psoriasis therapies to choose from, and several newer agents in development, physicians need up to date evidence for the use of these drugs. A PubMed search was conducted through August 1, 2014 to identify randomized controlled trials and systematic reviews of brodalumab for the treatment of psoriasis. Results of Phase I and II trials, as well as a few smaller studies, have provided promising data on efficacy, safety, health-related quality of life, pharmacokinetics, and changes in lesional skin. Early Phase III data continue to support the use of brodalumab as a potentially valuable option for the treatment of psoriasis. Keywords: anti-interleukin-17, psoriasis, biologic agents, efficacy, safety, systemic therapy
format	article
author	Sandoval LF Williams B Feldman SR
author_facet	Sandoval LF Williams B Feldman SR
author_sort	Sandoval LF
title	Clinical potential of brodalumab in the management of psoriasis: the evidence to date
title_short	Clinical potential of brodalumab in the management of psoriasis: the evidence to date
title_full	Clinical potential of brodalumab in the management of psoriasis: the evidence to date
title_fullStr	Clinical potential of brodalumab in the management of psoriasis: the evidence to date
title_full_unstemmed	Clinical potential of brodalumab in the management of psoriasis: the evidence to date
title_sort	clinical potential of brodalumab in the management of psoriasis: the evidence to date
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/e460669aee4546c284912a052ce96d84
work_keys_str_mv	AT sandovallf clinicalpotentialofbrodalumabinthemanagementofpsoriasistheevidencetodate AT williamsb clinicalpotentialofbrodalumabinthemanagementofpsoriasistheevidencetodate AT feldmansr clinicalpotentialofbrodalumabinthemanagementofpsoriasistheevidencetodate
_version_	1718399372229607424

Clinical potential of brodalumab in the management of psoriasis: the evidence to date

Ejemplares similares